BCL2L1 and cancer: With DT2216 already under clinical trial as the only PROTAC degrader for BCL-xL, our work here lays the foundation for advancing WH244 as a viable candidate for a BCL-xL/BCL-2 dual degrader for use as a cancer therapeutic.